In summary, we propose that the combination of nutraceutical and pharmacological strategies might provide the most benefit for HGPS treatment, by targeting the multifactorial detrimental effects of progerin expression in vivo. This evidence concerns the gene LMNA and Hutchinson-Gilford progeria syndrome.